Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7733048 | 1.00 | HSD17B1 (0.32) | HSD17B1MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7733030 | 1.00 | HSD17B1 (0.32) | HSD17B1MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7737030 | 0.86 | MEN1 (0.38) | MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7735247 | 0.83 | MEN1 (0.39) | HSD17B1MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7733008 | 0.82 | MEN1 (0.39) | MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7733024 | 0.82 | MEN1 (0.39) | MEN1POLBKMT2ACYP19A1 | |
| SCHEMBL7734509 | 0.81 | ACE (0.33) | MEN1POLBKMT2A | |
| SCHEMBL7733945 | 0.81 | — | — | |
| SCHEMBL7734459 | 0.81 | HSD17B3 (0.40) | MEN1POLBKMT2A | |
| SCHEMBL7734498 | 0.81 | HSD17B3 (0.40) | MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153683-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-7964632-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | HSD17B1 2161/4885MEN1 1699/4885POLB 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.